OA12505A - Method of inhibiting adhesion formation. - Google Patents

Method of inhibiting adhesion formation. Download PDF

Info

Publication number
OA12505A
OA12505A OA1200300271A OA1200300271A OA12505A OA 12505 A OA12505 A OA 12505A OA 1200300271 A OA1200300271 A OA 1200300271A OA 1200300271 A OA1200300271 A OA 1200300271A OA 12505 A OA12505 A OA 12505A
Authority
OA
OAPI
Prior art keywords
het
6alkyl
galkyl
alkyl
compound
Prior art date
Application number
OA1200300271A
Other languages
English (en)
Inventor
Robert N Willette
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of OA12505A publication Critical patent/OA12505A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200300271A 2001-04-10 2002-04-10 Method of inhibiting adhesion formation. OA12505A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28269301P 2001-04-10 2001-04-10

Publications (1)

Publication Number Publication Date
OA12505A true OA12505A (en) 2006-05-29

Family

ID=23082703

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300271A OA12505A (en) 2001-04-10 2002-04-10 Method of inhibiting adhesion formation.

Country Status (26)

Country Link
EP (1) EP1385504B1 (hu)
JP (1) JP4394882B2 (hu)
KR (1) KR20030087069A (hu)
CN (1) CN1248692C (hu)
AP (1) AP2003002894A0 (hu)
AT (1) ATE417612T1 (hu)
AU (1) AU2002305164B2 (hu)
BG (1) BG108217A (hu)
BR (1) BR0208789A (hu)
CA (1) CA2443734A1 (hu)
CZ (1) CZ20032767A3 (hu)
DE (1) DE60230404D1 (hu)
EA (1) EA006202B1 (hu)
EC (1) ECSP034799A (hu)
ES (1) ES2319877T3 (hu)
HU (1) HUP0303725A3 (hu)
IL (1) IL158272A0 (hu)
MA (1) MA26159A1 (hu)
MX (1) MXPA03009344A (hu)
NO (1) NO20034513L (hu)
NZ (1) NZ528577A (hu)
OA (1) OA12505A (hu)
PL (1) PL364526A1 (hu)
UA (1) UA75395C2 (hu)
WO (1) WO2002083125A1 (hu)
ZA (1) ZA200307621B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841406A4 (en) * 2004-12-21 2008-06-25 Smithkline Beecham Corp METHOD AND FORMULATIONS
RU2744540C1 (ru) * 2020-02-18 2021-03-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ профилактики спаечного процесса при операциях на брюшной полости в условиях паренхиматозного кровотечения в эксперименте

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
DE60230404D1 (hu) 2009-01-29
EA006202B1 (ru) 2005-10-27
NO20034513L (no) 2003-12-04
EP1385504A4 (en) 2007-03-14
NO20034513D0 (no) 2003-10-08
ATE417612T1 (de) 2009-01-15
ECSP034799A (es) 2004-01-28
AU2002305164B2 (en) 2005-07-28
HUP0303725A2 (hu) 2004-03-01
BR0208789A (pt) 2004-03-09
WO2002083125A1 (en) 2002-10-24
CN1509170A (zh) 2004-06-30
AP2003002894A0 (en) 2003-12-31
NZ528577A (en) 2005-01-28
IL158272A0 (en) 2004-05-12
CA2443734A1 (en) 2002-10-24
MA26159A1 (fr) 2004-07-01
MXPA03009344A (es) 2004-02-12
JP4394882B2 (ja) 2010-01-06
CN1248692C (zh) 2006-04-05
JP2004525959A (ja) 2004-08-26
EP1385504A1 (en) 2004-02-04
CZ20032767A3 (cs) 2004-12-15
HUP0303725A3 (en) 2009-08-28
ZA200307621B (en) 2004-04-21
KR20030087069A (ko) 2003-11-12
ES2319877T3 (es) 2009-05-14
BG108217A (bg) 2004-12-30
EA200301109A1 (ru) 2004-02-26
EP1385504B1 (en) 2008-12-17
PL364526A1 (en) 2004-12-13
UA75395C2 (en) 2006-04-17

Similar Documents

Publication Publication Date Title
Liu et al. Crosslinked hyaluronan hydrogels containing mitomycin C reduce postoperative abdominal adhesions
JP2003501151A (ja) 動脈再狭窄治療用装置および化合物
PT551182E (pt) Metodo para tratar a doenca vascular hiperproliferativa
US20050019366A1 (en) Drug-coated stents and methods of use therefor
EP1447096A1 (en) Remedies for urinary frequency
PL195136B1 (pl) Kombinacja zawierająca 5-[4-[2-(N-metylo-N-(2-pirydylo)amino)etoksy]-benzylo] tiazolidyno-2,4-dion i jej zastosowanie
HU212422B (en) Process for preparing pharmaceutical compositions containing dipyridamole for the treatment of proliferative diseases
PT1365808E (pt) Composições para tratamento antitumoral contendo ecteinascidina 743
JP2003519183A (ja) 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用
SK288707B6 (sk) Farmaceutické kombinácie obsahujúce antagonistu P2T receptora a ďalšie antitrombotické činidlá, spôsob ich prípravy a ich použitie na liečenie a prevenciu trombózy
BRPI0610498A2 (pt) uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
OA12505A (en) Method of inhibiting adhesion formation.
JP5244089B2 (ja) 鎮痛剤およびビタミンを含む医薬組成物
Cooper et al. Reduction of post-surgical adhesion formation with tranilast
AU2002305164A1 (en) Method of inhibiting adhesion formation
JP2004533462A (ja) 血管症の治療のための有機ナイトレートをベースとする化合物
JP2011148828A (ja) 非ウィルス性上皮損傷の治療および/または予防
Rodgers et al. Reduction of adhesion formation in rabbits by intraperitoneal administration of lazaroid formulations.
US20070149505A1 (en) Method of Inhibiting Adhesion Formation
US20100305144A1 (en) Prevention of recurrence of urethral stricture after a conventional treatment
CN108472333A (zh) 组合
JPH07196650A (ja) 平滑筋細胞増殖抑制作用を有するアルガトロバン製剤
WO2024088712A1 (en) Mglur5 receptor antagonists for use in prevention and/or treatment of bone marrow lesions (bml) and/or osteoporosis, cartilage loss, osteosclerosis, osteitis in a mammal
JP4955392B2 (ja) 血管内膜過増殖疾患の予防または治療剤
JP2003267876A (ja) 新規な血管狭窄治療剤又は予防剤